A Phase 1 interventional study of LY3410738 and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
The main purpose of this study is to assess the safety and tolerability of LY3410738 and to look at the amount of the study drug, LY3410738, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. For each participant, the total duration of the study will be 53 days, including screening.
Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule formulation.
Drug: LY3410738 · Drug: Placebo
Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule formulation.
Drug: LY3410738 · Drug: Placebo
Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
Drug: LY3410738 · Drug: Placebo
Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
Drug: LY3410738 · Drug: Placebo
Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
Drug: LY3410738 · Drug: Placebo
Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
Drug: LY3410738 · Drug: Placebo
Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
Drug: LY3410738 · Drug: Placebo
Administered orally.
Administered orally.
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through 53 days
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of LY3410738
PK: AUC0-24 of LY3410738
Time frame: Pre-dose up to 24 hours post-dose
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of LY3410738
PK: AUC0-t of LY3410738
Time frame: Pre-dose up to 48 hours post-dose
PK: Maximum Observed Plasma Concentration (Cmax) of LY3410738
PK: Cmax of LY3410738
Time frame: Pre-dose up to 48 hours post-dose
PK: Time to Maximum Observed Plasma Concentration (Tmax) of LY3410738
PK: Tmax of LY3410738
Time frame: Pre-dose up to 48 hours post-dose
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company